EOquin (Spectrum/Allergan) Phase III results in Bladder Cancer

Two double blind, randomized, placebo controlled, Phase III clinical trials for EOquin (apaziquone) as a treatment for Bladder Cancer did not meet their primary endpoint of a statistically significant difference in the rate of tumor recurrence at 2 years between the two arms. However, analysis of the pooled data from both studies showed a statistically significant treatment effect in favor of apaziquone in the primary endpoint of the rate of tumor recurrence at 2 years (p-value = 0.0174) and in a key secondary endpoint, time to recurrence (p-value = 0.0076). Spectrum will discuss further steps with the FDA.